[Conditional reimbursement: a tool to reduce uncertainty relating the value of medicines and reinforce their continuous evaluation in real-life].
In order to alleviate the inherent uncertainty that comes with the market access and public funding of new health products, a conditional reimbursement mechanism is proposed. The latter is circumscribed by recommendations regarding its implementation in limited cases in order to allow for a fair access of patients to therapeutic innovations, within economic conditions both optimum and reviewable.
GlaxoSmithKline France, 100, route Versailles, 78160 Marly-Le-Roi, France. Electronic address: jean-noel.g.bail@gsk.com.
J-N
JN
Bail
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005602:France; D012051:Reimbursement Mechanisms; D035501:Uncertainty
Accord; Agreement; Conditional Reimbursement; Incertitude; Innovation; Medicine; Médicament; Price; Prix; Remboursement conditionnel; Uncertainty; Valeur; Value